Kezar Life Sciences, Inc. (KZR)
| Market Cap | 251.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.38M |
| Shares Out | 50.00M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $5.32 |
| Previous Close | $5.42 |
| Change ($) | -0.10 |
| Change (%) | -1.85% |
| Day's Open | 5.47 |
| Day's Range | 5.22 - 5.49 |
| Day's Volume | 120,995 |
| 52-Week Range | 2.77 - 7.75 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-media...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-medi...
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and...
Kezar is a young company with two candidates in clinical development. Development programs with broad therapeutic potential.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-medi...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-medi...
SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncol...
SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncol...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.
Kezar Life Sciences: Exploring New Options For Autoimmune Diseases
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. (KZR) CEO John Fowler on Q2 2020 Results - Earnings Call Transcript
SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncol...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.
The company's public offering of common stock doesn't exactly thrill investors.
Kezar Life Sciences just released interim results on its only drug and shares jumped 70%. Now that the stock has settled, is it a good time to buy?
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...
Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...
Kezar Life Sciences (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Ranked Momentum Stocks to Buy for May 11th
SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics t...
SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecul...
Is (KZR) Outperforming Other Medical Stocks This Year?
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Wall Street sell-side analysts recommend buying shares of Aurora Mobile Limited (NASDAQ:JG) and Kezar Life Sciences Inc (NASDAQ:KZR), two falling knives whose share prices lost more than 59% o...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecul...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Shares of Kezar Life Sciences Inc (NASDAQ: KZR) have retreated to a fresh 52-week low on roughly five times their average volume.
Kezar Life Sciences Inc. shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus (SLE).
About KZR
Kezar Life Sciences, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and... [Read more...]
| Industry Biotechnology | IPO Date Jun 21, 2018 |
| CEO John Fowler | Employees 40 |
| Stock Exchange NASDAQ | Ticker Symbol KZR |
Analyst Forecasts
According to 5 analysts, the average rating for KZR stock is "Strong Buy." The 12-month stock price forecast is 14.67, which is an increase of 175.75% from the latest price.